- Home
- VSTM vs CLYM Comparison
VSTM vs CLYM Comparison
Compare VSTM & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VSTM
- CLYM
- Stock Information
- Founded
- VSTM 2010
- CLYM 2018
- Country
- VSTM United States
- CLYM United States
- Employees
- VSTM N/A
- CLYM N/A
- Industry
- VSTM Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- VSTM Health Care
- CLYM
- Exchange
- VSTM Nasdaq
- CLYM NYSE
- Market Cap
- VSTM 239.9M
- CLYM 201.7M
- IPO Year
- VSTM 2012
- CLYM 2021
- Fundamental
- Price
- VSTM $4.22
- CLYM $1.95
- Analyst Decision
- VSTM Strong Buy
- CLYM
- Analyst Count
- VSTM 8
- CLYM 0
- Target Price
- VSTM $12.00
- CLYM N/A
- AVG Volume (30 Days)
- VSTM 1.1M
- CLYM 264.1K
- Earning Date
- VSTM 11-06-2024
- CLYM 11-12-2024
- Dividend Yield
- VSTM N/A
- CLYM N/A
- EPS Growth
- VSTM N/A
- CLYM N/A
- EPS
- VSTM N/A
- CLYM N/A
- Revenue
- VSTM $10,000,000.00
- CLYM N/A
- Revenue This Year
- VSTM N/A
- CLYM N/A
- Revenue Next Year
- VSTM $53.90
- CLYM N/A
- P/E Ratio
- VSTM N/A
- CLYM N/A
- Revenue Growth
- VSTM N/A
- CLYM N/A
- 52 Week Low
- VSTM $2.10
- CLYM $1.86
- 52 Week High
- VSTM $14.22
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- VSTM 47.50
- CLYM N/A
- Support Level
- VSTM $4.18
- CLYM N/A
- Resistance Level
- VSTM $4.85
- CLYM N/A
- Average True Range (ATR)
- VSTM 0.42
- CLYM 0.00
- MACD
- VSTM -0.14
- CLYM 0.00
- Stochastic Oscillator
- VSTM 10.70
- CLYM 0.00
About VSTM Verastem Inc.
Verastem Inc is late-stage development biopharmaceutical company, committed to advancing new medicines for patients battling cancer. Its pipeline is focused on novel anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly RAF/MEK inhibition and FAK inhibition.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.